Lack of women CEOs is a problem for healthcare, Oliver Wyman says

Healthcare IT News | January 08, 2019

More than 80 percent of the decisionmakers in the U.S. healthcare workforce are women — and 65 percent of women in C-suite healthcare positions fill technical or influencer roles — yet only 13 percent make it to CEO, according to the latest Oliver Wyman report. And, when they do make it to the top, it takes 3.5 years longer. The report, released Jan. 7, was based on a study of 3,000 healthcare C-suite executives and board members across the U.S and the career paths of 112 CEOs. Oliver Wyman analysts interviewed more than 75 men and women in the industry to try and understand “the visible and invisible dynamics women face,” and they discovered it’s “much harder” for women to earn the trust of their peers, when at the top it is mainly male dominated. “The closer women get to the top, the less diversity exists, and the more dominant male perceptions and unintentional biases become,” the researchers said.

Spotlight

In this "What is video" Healthcare professor Brecht Cardoen and Finance Professor Filip Roodhooft explain what Value-based healthcare is and what is means for the medical industry.


Other News
FUTURE OF HEALTHCARE

Dalrada Accelerates Its National Healthcare Model With Acquisition of Watson Rx Solutions

Dalrada Corporation | June 09, 2022

Dalrada Corporation announced that it had acquired the pharmacy, Watson Rx Solutions, Inc. The move highlights Dalrada’s aggressive growth plans within the healthcare sector and paves the way for a total end-to-end total healthcare solution. Adding the 10-year-old pharmacy to Dalrada Health’s comprehensive model expands the subsidiary’s synergies with potential opportunities across its products and services portfolio and offers another solution to meet patient requirements. Dalrada envisions a comprehensive healthcare solution for all Dalrada Health clients with unique offerings that will now include: a pharmacy to facilitate prescription processing, physicians and clinicians at treatment clinics, expanding into telemedicine, engagement of Dalrada-owned testing facilities and laboratories, and utilization of Company-specific technologies to facilitate immediate growth of the business. “Watson Rx has a long history of providing excellent pharmacy services. This acquisition allows Dalrada to expand its healthcare footprint and continue to build a total health management solution on an already successful turnkey operation. As a result, the Company will be able to successfully address the health needs of even more patients.” CEO and Founder, Brian Bonar Through comprehensive prescription management, education, nursing, and total health management, Watson Rx Solutions' leadership team holds more than six decades of combined experience in various complex pharmacy disease states and retail services, always putting patients first. Dalrada plans on entering the pharmaceutical space with an accelerated strategic plan to leverage the Company’s existing capabilities. Research reveals that the U.S. online and mail-order sales of drugs, health, and beauty aids were valued at 75.5 billion USD in 2020. Additionally, E-commerce pharmaceutical sales and beauty aids increased from 51.7 billion USD the year prior. Online, E-commerce, and mail-order sales increased from around 31 to 38 percent during the same period. Pharmacy and drug store sales reached 300 billion USD in 2020, with over-the-counter (OTC) medication accounting for over 36 billion USD in sales during the same year, the highest-selling year to date for the OTC segment. Dalrada and its subsidiaries provide value by making timely and impactful products and services available within health, technology, and clean energy markets. About Dalrada Dalrada Corporation drives innovation that positively impacts people, businesses, and the planet. With subsidiaries that are firmly positioned in the world’s top three-growing industries of healthcare, clean energy, and technology, Dalrada creates solutions that are sustainable, affordable, and accessible. The company works continually to produce disruptive products and services that accelerate positive change for current and future generations. Dalrada’s global solutions directly address climate change, post-pandemic gaps in the healthcare industry, and technology solutions for a new era of human behavior and interaction, ensuring a bright future for the world around us.

Read More

HEALTH TECHNOLOGY

Microba Life Sciences Signs Partnership With Nib-Backed Midnight Health

Microba Life Sciences Limited | May 26, 2022

Microba Life Sciences Limited has signed a strategic partnership agreement with nib Holdings Limited backed digital healthcare company Midnight Health, to deliver a personalised health service to the Australian consumer market. Under this Agreement, Midnight Health will promote, market and sell a world-first subscription-based service, known as Vidality, with its network of pharmacists to formulate personalised supplements for each customer based on their microbiome test results, leveraging the recommendations from Microba’s Analysis Platform. This personalised, pharmacy-integrated service model – delivered with trained, registered pharmacists – will bring a level of science and personalisation to an industry which commonly provides customers with one-size-fits-all solutions. Midnight Health CEO, Nic Blair said: “We are experiencing strong demand for innovative online healthcare solutions aligned to an individual needs. We already have more than 13,000 subscribers across our existing brands with strong month-on-month growth. Many of our customers are looking for gut health solutions and we are proud to bring the Vidality product to our customers in partnership with Microba”. The Agreement was signed, for an initial period of 3 years, after a successful pilot which tested the service model and product offering. It further demonstrates Microba’s scalable technology and ability to deliver evidence-based gut health solutions together with distribution partners. “Consumers are seeking personalised, evidence-based solutions to support their gut health. Together with Midnight Health, we are excited to bring the Vidality product to consumers, a truly personalised solution powered by our technology”. Microba CEO, Dr Luke Reid This delivers on an undertaking in the Company’s Prospectus to enter into an Australian partnership with a fast growth innovative consumer healthcare company. This announcement has been authorised for release by the Board. About Midnight Health Midnight Health delivers innovative online healthcare solutions through a patient-led digital platform. With the primary goal of democratising healthcare and enabling individuals to take control of their own healthcare, Midnight Health integrate telehealth technology, doctors, pharmacy network and other partners to provide a seamless patient experience for fast, convenient and discreet access to treatments, prescriptions and education through niche digital brand platforms. About Microba Life Sciences Limited Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.

Read More

FUTURE OF HEALTHCARE

Virta Health Highlights Lasting, Transformative Health Improvements In 5-Year Diabetes Reversal Study

Virta Health | June 07, 2022

Virta Health, the leader in type 2 diabetes reversal, revealed preliminary five-year results from its landmark clinical trial at the American Diabetes Association 82nd Scientific Sessions. Presenting four unique abstracts, Virta highlighted myriad, lasting health improvements for people with type 2 diabetes and prediabetes, including blood sugar control, clinically-significant weight loss, reduced inflammation, and improvements in other markers of cardiometabolic health. These transformative health outcomes coincided with medication reduction or elimination for many trial patients, including Jane Ann Dimitt. For over two decades, Jane Ann was prescribed increasing levels of medications as her blood sugar and weight continued to climb. By the time she joined Virta in 2015, her A1c had reached 11.4%; the next step was insulin. Through Virta’s treatment, Jane Ann lowered her blood sugar to 5.5% (below even the prediabetes threshold) and lost over 50 pounds, while drastically reducing her reliance on medications. She also saw improved mobility, decreased inflammation and neuropathy, and now has the energy to play with her grandchildren—all without needing the insulin doctors said was imminent. The outcomes of Jane Ann and Virta’s other trial patients contradict the belief that progression of diabetes—and a lifetime of increasing medications—is inevitable. One-fifth of Virta patients completing five years of treatment saw full remission. One-third of patients achieved A1c below 6.5% without any diabetes medications, or only requiring Metformin. Notably, inflammatory markers, triglycerides, and HDL cholesterol all improved significantly. These outcomes, in conjunction with previous research demonstrating improvements in cardiovascular disease risk factors, depression symptoms, sleep, and knee pain, establish the promise of Virta’s approach to impact a wide range of conditions amid America’s metabolic disease epidemic. In the U.S., costs are rising as patient outcomes continue to worsen, including surges in amputations, hyperglycemic events, and diabetes-related deaths during the COVID-19 pandemic. Meanwhile, getting patients to stick with an intervention remains a significant challenge in diabetes therapy. Rates of medication adherence—that is, whether patients take their medications as prescribed—fall as low as 34% over the first three years for those starting insulin. For the National Diabetes Prevention Program, considered the gold standard in lifestyle interventions, only 13% of patients were retained at one year. In contrast, in Virta’s trial nearly 50% of participants with type 2 diabetes were retained at five years. Of those who continued past year two, 72% remained for an additional three years to year five. For Kim Shepherd, who lost 55 pounds, eliminated 10 different medications, reversed her diabetes, and even saw her GERD (acid reflux) and plantar fasciitis disappear, the reasons to stick with the treatment are clear. “Diabetes runs in my family, and I know that this disease can rob you of your whole life; it can take your eyes, your feet, and your kidneys. I have 4 kids and 9 grandkids to keep up with. I’ve learned to love hiking and biking. Nothing is worth losing all of that and going back to how I was before.” Additional key outcomes demonstrating the success of Virta’s approach at five years include Sustained blood sugar control. Virta patients experienced persistent improvements in blood sugar on average, while requiring significantly fewer medications. Medication deprescription. Half of patients prescribed insulin at the start of the trial no longer needed it at five years. Across all diabetes drugs, prescriptions were reduced by nearly 50%. Weight loss. Average weight among Virta participants decreased by 7.6%, exceeding the 5% benchmark for clinically significant weight loss by more than 50%. Broad improvement in cardiometabolic health. In addition to improvements in triglycerides, HDL cholesterol, and markers of inflammation, patients even showed encouraging signs in reversing the progression of chronic kidney disease. “Virta’s patients are helping redefine what long-term success can look like in type 2 diabetes care. The patient outcomes set a new standard for real-world applications of diabetes treatment." Dr. Alan Moses, former Senior Vice President and Global Chief Medical Officer of Novo Nordisk, and Virta advisor Trial participants with prediabetes also saw meaningful improvements, with progression rates far below what has been demonstrated in other studies. Further, Virta patients sustained 6% weight loss over five years, exceeding the clinically-significant benchmark for diabetes prevention and far surpassing the 2% weight loss observed in the NIH Diabetes Prevention Program lifestyle intervention. The study is also notable for its longevity. Five-year published results are extremely rare in digital health, where most studies follow populations for no more than a year, and usually significantly less. For many Virta patients, the five-year clinical trial has facilitated a lasting lifestyle change, improving not only traditional markers of health but overall mood, quality of life, and outlook on the future. Says patient Denise Lamb, who has maintained diabetes reversal alongside a nearly 70 pound weight loss, “My journey has been phenomenal. The Virta program has not only helped me achieve healthy blood glucose, but also attain a far better weight, normal blood pressure, and better understanding of my body. Virta’s lifestyle changed my lifestyle!” About Virta Health Virta Health helps people reverse type 2 diabetes and other chronic conditions. Current approaches manage disease progression through increased medication use and infrequent doctor visits. Virta reverses type 2 diabetes through innovations in technology, nutrition science, and continuous remote care from physicians and behavioral experts. In clinical studies, 94% of patients reduce or eliminate insulin use, and weight-loss exceeds FDA benchmarks by nearly 150%. Virta works with the largest health plans, employers, and government organizations and puts 100% of its fees at risk based on clinical and financial outcomes.

Read More

HEALTH TECHNOLOGY

BulletinHealthcare Launches Family Medicine Today in Partnership with American Academy of Family Physicians

BulletinHealthcare | August 16, 2022

BulletinHealthcare, a leading provider of news briefings for top U.S. medical associations, announced that it has launched its latest briefing for members of the American Academy of Family Physicians Family Medicine Today. Family Medicine Today is distributed via email to AAFP members by 9:00 a.m. ET every weekday morning. The publication provides family medicine physicians with relevant medical, practice management, and health policy news, delivered directly to their inbox in a concise, user-friendly format. The content of the briefings follows BulletinHealthcare's signature curation and distillation of the day's most important news stories, selected from thousands of sources by its team of healthcare analysts. "We are pleased to partner with the American Academy of Family Physicians to produce an exciting publication to serve their members. Our analyst group is unmatched in their expertise in producing handcrafted news briefings for busy healthcare professionals. And, with this new partnership, BulletinHealthcare adds a valuable new audience to the nearly one million healthcare professionals we reach each day." Danielle Sturgis, Vice President of Partnerships at BulletinHealthcare "The typical family physician sees more than 80 patients a week. As advocates for family physicians and their patients, the AAFP works to deliver high-value resources that give our members more time and energy for their patients," said Shawn Martin, Executive Vice President and Chief Executive Officer of the American Academy of Family Physicians. "In Family Medicine Today, BulletinHealthcare will curate content specifically for family physicians, providing a quick and convenient way for our members to stay current on news and trends that affect family medicine." Advertising opportunities in AAFP's Family Medicine Today are now available, including special founding advertiser packages for 2022. About BulletinHealthcare BulletinHealthcare, a Cision® Insights solution, is a healthcare provider-focused digital publisher that – through partnerships with more than 30 leading medical associations and the Cleveland Clinic – curates and disseminates the stories and research that matter most to verified physicians, dentists, nurses, and other HCPs. BulletinHealthcare delivers nearly one million briefings every weekday to our partners' members and stakeholders. About the American Academy of Family Physicians Founded in 1947, the AAFP represents 127,600 physicians and medical students nationwide. It is the largest medical society devoted solely to primary care. Family physicians conduct approximately one in five office visits -- that's 192 million visits annually or 48 percent more than the next most visited medical specialty. Today, family physicians provide more care for America's underserved and rural populations than any other medical specialty. Family medicine's cornerstone is an ongoing, personal patient-physician relationship focused on integrated care.

Read More